Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma-Reference-Cited by-同舟云学术

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma

Published:2011-07 Issue:1 Volume:122 Page:116-120
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Weroha S. John,Oberg Ann L.,Ziegler Katie L. Allen,Dakhilm Shaker R.,Rowland Kendrith M.,Hartmann Lynn C.,Moore Dennis F.,Keeney Gary L.,Peethambaram Prema P.,Haluska Paul

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference40 articles.

1. Cancer statistics;Jemal,2010

2. SEER Cancer Statistics Review, 1975–2006;Horner,2009

3. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan;Gordon;J Clin Oncol,2001

4. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;ten Bokkel Huinink;J Clin Oncol,1997

5. International Topotecan Study G. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma;ten Bokkel Huinink;Ann Oncol,2004

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer;Journal of Experimental & Clinical Cancer Research;2024-02-26

2. Characterization of global research trends and prospects on platinum-resistant ovarian cancer: a bibliometric analysis;Frontiers in Oncology;2023-06-05

3. Herbal Medicines as Adjuvants for the Treatment of Chemotherapy-Induced Diarrhea;Current Drug Metabolism;2023-06

4. Characterization of Global Research Trends and Prospects on Platinum-Resistant Ovarian Cancer: A Bibliometric Analysis (Preprint);2023-01-21

5. Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer;Frontiers in Oncology;2022-06-15